



OPEN ACCESS

ORIGINAL ARTICLE

Inherited mutations in *BRCA1* and *BRCA2* in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia

Wei Xiong Wen,¹ Jamie Allen,² Kah Nyin Lai,¹ Shivaani Mariapun,¹ Siti Norhidayu Hasan,¹ Pei Sze Ng,¹ Daphne Shin-Chi Lee,¹ Sheau Yee Lee,¹ Sook-Yee Yoon,¹ Joanna Lim,¹ Shao Yan Lau,¹ Brennan Decker,^{2,3} Karen Pooley,² Leila Dorling,² Craig Luccarini,⁴ Caroline Baynes,² Don M Conroy,² Patricia Harrington,² Jacques Simard,⁵ Cheng Har Yip,^{1,6} Nur Aishah Mohd Taib,^{7,8} Weang Kee Ho,⁹ Antonis C Antoniou,² Alison M Dunning,⁴ Douglas F Easton,^{2,4} Soo Hwang Teo^{1,7}

For numbered affiliations see end of article.

Correspondence to

Professor Soo Hwang Teo,
Cancer Research Malaysia, 1
Jalan SS12/1A, 47500 Subang
Jaya, Selangor, Malaysia;
soohwang.teo@cancerresearch.
my

Received 27 July 2017
Revised 3 September 2017
Accepted 8 September 2017
Published Online First
9 October 2017

ABSTRACT

Background Genetic testing for *BRCA1* and *BRCA2* is offered typically to selected women based on age of onset and family history of cancer. However, current internationally accepted genetic testing referral guidelines are built mostly on data from cancer genetics clinics in women of European descent. To evaluate the appropriateness of such guidelines in Asians, we have determined the prevalence of germ line variants in an unselected cohort of Asian patients with breast cancer and healthy controls.

Methods Germ line DNA from a hospital-based study of 2575 unselected patients with breast cancer and 2809 healthy controls were subjected to amplicon-based targeted sequencing of exonic and proximal splice site junction regions of *BRCA1* and *BRCA2* using the Fluidigm Access Array system, with sequencing conducted on a Illumina HiSeq2500 platform. Variant calling was performed with GATK UnifiedGenotyper and were validated by Sanger sequencing.

Results Fifty-five (2.1%) *BRCA1* and 66 (2.6%) *BRCA2* deleterious mutations were identified among patients with breast cancer and five (0.18%) *BRCA1* and six (0.21%) *BRCA2* mutations among controls. One thousand one hundred and eighty-six (46%) patients and 97 (80%) carriers fulfilled the National Comprehensive Cancer Network guidelines for genetic testing.

Conclusion Five per cent of unselected Asian patients with breast cancer carry deleterious variants in *BRCA1* or *BRCA2*. While current referral guidelines identified the majority of carriers, one in two patients would be referred for genetic services. Given that such services are largely unavailable in majority of low-resource settings in Asia, our study highlights the need for more efficient guidelines to identify at-risk individuals in Asia.

response.¹ The majority of studies have hitherto screened high-risk patients with breast cancer selected on the basis of age, family history and, some studies, tumour subtype, such as oestrogen receptor negative or triple negative breast cancer (TNBC).² These studies have reported the prevalence of deleterious germ line variants in *BRCA1* and *BRCA2* among Asian high-risk patients with breast cancer is similar to that in other populations, ranging between 10% and 20%.^{2–6} However, it is estimated that less than 1% of the 560 000 patients with breast cancer diagnosed in 14 Asian countries each year benefit from genetic testing services, because of high cost and limited accessibility.⁷ In such resource-limited settings, it is critical to have appropriate guidelines for referral for genetic testing. While internationally accepted clinical criteria for referral can be obtained from the National Comprehensive Cancer Network (NCCN) guidelines on genetic/familial high-risk assessment,⁸ such guidelines have been developed primarily from data from population of European ancestry. There are established differences in breast cancer epidemiology between Asian and Caucasian individuals,⁹ but the appropriateness of such guidelines in identifying mutation carriers have hitherto not been assessed in Asian populations.

To evaluate current genetic testing referral guidelines, we have conducted an analysis of *BRCA1* and *BRCA2* in a multiethnic cohort of unselected patients with breast cancer of Chinese, Malay and Indian ethnicity from Malaysia. Our study provides data on the appropriateness of current guidelines for identifying individuals at higher risk of carrying germ line variants in *BRCA1* and *BRCA2* and lays the foundation for developing risk assessment tools for Asian populations.

METHODS

Study populations

We included patients with breast cancer and control subjects who participated in the Malaysian Breast Cancer Genetic Study between October 2002 and March 2015. Incident and prevalent cases and controls were recruited from two hospitals: University Malaya Medical Centre and Sime Darby

INTRODUCTION

Genetic testing for mutations in *BRCA1* and *BRCA2* has led to the identification of individuals at higher risk of breast cancer, enabled risk-stratified approaches for management of risk in relatives and enabled the selection of individuals who may benefit from therapies targeting the DNA damage



To cite: Wen WX, Allen J, Lai KN, et al. *J Med Genet* 2018;**55**:97–103.

Medical Centre.^{10 11} Of the 2870 patients with breast cancer and 2999 control subjects recruited, 2575 and 2809 cases and controls, respectively, were included in this study (see tables 1 and 2 in the online supplementary file 1 for exclusion criteria). Of these 2575 cases, 887 (34%) women were considered to be a priori high or moderate risk and had been previously tested for germ line alterations in *BRCA1* and *BRCA2* by Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) analysis as described.^{12–15} All study participants provided written informed consent. The study was approved by the Medical Ethics Committee of University Malaya Medical Centre (application number: 842.9) and the Independent Ethics Committee of Sime Darby Medical Centre (application numbers: 201109.4 and 201208.1).

Sequencing library preparation and sequencing

Fluidigm D3 design software (Fluidigm, San Francisco, California, USA) was used to design a targeted sequencing panel that included the coding sequences and intron/exon boundaries of coding exons from 31 known or suspected breast cancer susceptibility genes, including *BRCA1* and *BRCA2*. Target sequence enrichment was performed using 48.48 Fluidigm Access Arrays (Fluidigm, San Francisco, California, USA) then sequenced on Illumina Hi-Seq2500 instrument (Illumina, San Diego, California, USA) according to the manufacturer's protocol as previously described.¹⁶ The median read depth across the 261 amplicons covering the *BRCA1* and *BRCA2* coding sequence was 673 (IQR 534–909).

Bioinformatics analysis

Sequenced reads were demultiplexed and converted from the Illumina binary format into FASTQ format. Next, adaptor sequences were trimmed using Cutadapt (<https://pypi.python.org/pypi/cutadapt>). Sequenced reads were then aligned against the human genome reference sequence (hg19) with Burrows-Wheeler Aligner.¹⁷ Subsequent local insertion/deletion (indel) realignment and base quality score recalibration were performed using the Genome Analysis Toolkit (GATK; <https://www.broadinstitute.org/gatk>). Genetic variants were called with GATK Unified Genotyper using the default parameters except $-\text{minIndelFrac}$ (set to 0.05).¹⁸ Variants were annotated using ANNOVAR (<http://www.openbioinformatics.org/annovar>)¹⁹ and missense variants were further annotated using Align-GVGD (<http://agvgd.iarc.fr>).²⁰ Nonsense, frameshift, canonical splice site variants (positions -2 and -1 upstream of an exon start and $+1$ and $+2$ downstream of an exon end) and single nucleotide variants classified as Class 4 or Class 5 according to BRCA Mutation Database (<http://arup.utah.edu/database/BRCA/>) or Leiden Open Variation Database were considered deleterious, except for variants located at the C-terminal of *BRCA1* and *BRCA2* (amino acid position 1856–1863 and 3326–3385, respectively). All deleterious and non-C0 variants as per Align-GVGD were validated by Sanger sequencing.

Statistical analysis

Analyses were based on the variants identified through the analysis of the Next generation sequencing data only. Carriers of large genomic rearrangement (LGR), non-LGR deleterious variants and variants of unknown significance (VUS) previously identified but not detected in this sequencing study were considered as non-carriers. Categorical and continuous variables were compared using χ^2 test and t-test, respectively. Statistical tests

were considered significant based on two-sided hypothesis tests with $p < 0.05$.

NCCN guidelines and MyCPG for *BRCA1* and *BRCA2* testing

The NCCN guidelines V.1.2017 and Malaysian Clinical Practice Guidelines (MyCPG)⁹ for genetic testing of *BRCA1* and *BRCA2* for BRCA-related breast and ovarian cancer syndrome were used to identify patients with breast cancer and *BRCA1* and *BRCA2* carriers whom met testing criteria for *BRCA1* and *BRCA2* screening. The NCCN guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. The MyCPG are meant to be guides for clinical practice in Malaysia based on the best available evidence at the time of development. *BRCA1* and *BRCA2* testing criteria for both guidelines used in this study are described in table 1.

RESULTS

Study population

Comparisons of the characteristics of breast cancer cases and the healthy women attending opportunistic screening mammography are shown in table 2 and table 3 in the online supplementary file 1. Approximately two-thirds of cases and controls were of Chinese ancestry. Patients with breast cancer were, on average, younger than the controls and enriched for family history of breast cancers up to second degree.

BRCA1 and *BRCA2* mutations and VUS

Of the 2575 patients with breast cancer, 55 (2.1%) carried deleterious variants in *BRCA1* and 66 (2.6%) had deleterious variants in *BRCA2* (table 3). The frequency of deleterious variants was similar in Indian (7.5%) and Malay patients (6.7%), but lower in Chinese patients (3.5%, $p < 0.01$). *BRCA2* deleterious variants were more common than *BRCA1* deleterious variants among Chinese patients (2.3% vs 1.2%) but less common

Table 1 Comparison of screening criteria between NCCN and MyCPG

Category	NCCN and MyCPG	
Personal history of cancer	Ovarian cancer	
	Bilateral breast cancer ≤ 50 years old	
Family history of cancer	Male breast cancer	
	Ovarian cancer	
	Proband ≤ 50 years old $+\geq 1$ close blood relative with breast cancer	
Category	NCCN	MyCPG
Personal history of cancer	Primary breast cancer ≤ 45 years old	Primary breast cancer ≤ 35 years old
Family history of cancer	Proband any age $+\geq 1$ close blood relative with breast cancer ≤ 50 years old	Proband any age $+\geq 2$ close blood relative with breast cancer ≤ 50 years old
	Proband any age $+\geq 2$ close blood relative with breast cancer	Proband any age $+\geq 3$ close blood relative with breast cancer
	Proband ≤ 50 years old $+\geq 1$ close blood relative with pancreatic cancer	
	Proband any age $+\geq 2$ close blood relative with pancreatic cancer	
Pathology	TNBC ≤ 60 years old	TNBC ≤ 50 years old

MyCPG, Malaysian Clinical Practice Guidelines; NCCN, National Comprehensive Cancer Network; TNBC, triple negative breast cancer.

Table 2 Demographic characteristics and known breast cancer risk factors of study participants*

Category	Cases (n=2575)	Controls (n=2809)	p Value
Demographic factors			
Age (year±SD)	50.0±10.8	52.6±8.2	<0.001
Age distribution			
<30	67 (2.6)	0	<0.001
30–39	351 (13.9)	10 (0.4)	
40–49	821 (32.4)	1101 (39.3)	
50–59	804 (31.7)	1087 (38.8)	
≥60	490 (19.3)	607 (21.6)	
Ethnicity			
Chinese	1726 (67.0)	1686 (60.0)	<0.001
Malay	490 (19.0)	547 (19.5)	
Indian	359 (13.9)	576 (20.5)	
Family history			
Number of first-degree relatives with breast cancer			
0	2224 (86.4)	2454 (87.5)	0.061
1	309 (12.0)	304 (10.8)	
2	35 (1.4)	45 (1.6)	
3	7 (0.3)	1 (0.04)	
Number of second-degree relatives with breast cancer			
0	2322 (90.2)	2640 (94.2)	<0.001
1	219 (8.5)	148 (5.3)	
2	30 (1.2)	14 (0.5)	
3	3 (0.1)	2 (0.1)	
4	1 (0.04)	0	

*Unless otherwise specified, data are presented in no. (%). For each data type, the total number of subjects may differ because of missing or incomplete data.

in Indian patients (2.8% vs 5.0%), while the frequencies were similar in Malay patients (3.3% vs 3.5%; $p < 0.01$ for difference in *BRCA1:BRCA2* ratio).

Of 2809 control subjects, five (0.18%) had deleterious variants in *BRCA1* and six (0.21%) had deleterious variants in *BRCA2* (table 3). The deleterious variant frequencies of *BRCA1* and *BRCA2* in the controls were similar to those in the Exome Aggregation Consortium East Asian population with reported deleterious variant frequencies of 0.16% and 0.21% for *BRCA1* and *BRCA2*, respectively.

Deleterious variants in *BRCA1* and *BRCA2* were significantly more common in breast cancer cases compared with control subjects, with estimated ORs for breast cancer of 12.6 (95% CI 5.0 to 31.4) and 12.6 (95% CI 5.4 to 29.0) for *BRCA1* and *BRCA2*, respectively.

VUS in *BRCA1* were reported in 12 cases (0.47%) versus four controls (0.14%) ($p = 0.03$). In contrast, there was no difference in the frequency of VUS in *BRCA2* in cases versus controls (30 (1.2%) cases versus 39 (1.4%) controls ($p = 0.70$); tables 4 and 5 in the online supplementary file 1).

One hundred and twenty-five of 887 a priori moderate-risk to high-risk patients previously screened had *BRCA1* germ line variants (nine LGR, 54 non-LGR deleterious variants and 63 missense, intronic, synonymous and inframe variants) and 242 had *BRCA2* germ line variants (four LGR, 49 non-LGR variants and 191 missense, intronic, synonymous and inframe variants). Of these, 98 *BRCA1* and 221 *BRCA2* variants were detected using this amplicon-based method, giving a sensitivity of 89% (95% CI 86% to 92%, not inclusive of LGR). When examined, the variants missed by the amplicon sequencing method all showed preferential amplification of the wild-type allele (and hence were excluded due to high allelic imbalance) or had low amplicon coverage. Sensitivity for non-LGR deleterious variants was similar (90%; 95% CI 85% to 96%) with 49 of 54 *BRCA1* and 44 of 49 *BRCA2* deleterious variants detected.

Types and spectrum of deleterious variants

Ninety-seven distinct deleterious variants (41 *BRCA1* and 56 *BRCA2*) and 11 distinct deleterious variants (five *BRCA1* and 6 *BRCA2*) were identified in breast cancer cases and control subjects, respectively (online supplementary file 1). Notable recurrent variants were *BRCA1* c.68_69delAG, *BRCA1* c.2635G>T and *BRCA2* c.262_263CT. *BRCA1* c.68_69delAG was observed exclusively in the Indians and constituted 4 of 17 (24%) of *BRCA1* deleterious mutations reported in Indian breast cancer cases. *BRCA1* c.2635G>T, a reported mutation among Southern Chinese,²¹ was identified in two Chinese and one Malay breast cancer cases. Interestingly, principal component analysis derived from previous genome-wide genotyping data suggested that this Malay individual is of mixed Chinese and Malay descent (data not shown).²² *BRCA2* c.262_263CT contributed 7 of 16 (44%) of *BRCA2* variants found in the Malay patients with breast cancer and one in two (50%) *BRCA2* variants in Malay control subjects.

Clinicopathological characteristics of deleterious variant carriers

BRCA1 and *BRCA2* carriers were more likely to be diagnosed at a younger age compared with non-carriers (table 4; mean ages at diagnosis 41, 46, and 50 years old, respectively). While 49% of patients with breast cancer were diagnosed before the age of 50, 72% of *BRCA1* and *BRCA2* carriers were diagnosed before the

Table 3 Mutation frequencies of *BRCA1* and *BRCA2* in breast cancer cases compared with population*

Class	Cases (n=2575)	Controls (n=2809)	ExAC EA (n=4327)	OR (95% CI)†	OR (95% CI)‡
Non-carriers	2412 (93.7%)	2755 (98.1%)	4259 (98.4%)	1.00 (reference)	1.00 (reference)
BRCA1					
Deleterious	55 (2.1)	5 (0.2)	7 (0.2)	12.6 (5.0 to 31.4)	13.9 (6.3 to 30.5)
VUS	12 (0.5)	4 (0.1)	6 (0.1)	3.4 (1.1 to 10.6)	3.5 (1.3 to 9.4)
BRCA2					
Deleterious	66 (2.6)	6 (0.2)	9 (0.2)	12.6 (5.4 to 29.0)	12.9 (6.4 to 26.0)
VUS	30 (1.2)	39 (1.4)	46 (1.1)	0.9 (0.5 to 1.4)	1.2 (0.7 to 1.9)

*Unless otherwise specified, data are presented in no. (%)

†Cases versus controls.

‡Cases versus ExAC EA.

EA: East Asian; ExAC: Exome Aggregation Consortium; VUS, variants of unknown significance.

Cancer genetics

Table 4 Association between *BRCA1* and *BRCA2* mutation status and clinicopathological characteristics^a

Clinical variables	<i>BRCA1</i> carriers (n=55)	<i>BRCA2</i> carriers (n=66)	Non-carriers (n=2454)	p Value†	p Value‡
Age (year±SD)	40.8±10.6	45.7±10.8	50.3±10.7	<0.001	0.001
Age distribution					
<30	9 (16.4)	2 (3.1)	56 (2.3)	<0.001	0.001
30–39	19 (34.5)	20 (30.8)	312 (12.9)		
40–49	15 (27.3)	21 (32.3)	785 (32.5)		
50–59	10 (18.2)	12 (18.5)	782 (32.4)		
≥60	2 (3.6)	10 (15.4)	478 (19.8)		
Family history of breast cancer up to first degree					
No	37 (67.3)	47 (71.2)	2143 (87.3)	<0.001	<0.001
Yes	18 (32.7)	19 (28.8)	311 (12.7)		
Family history of breast cancer up to second degree					
No	32 (58.2)	41 (62.1)	1952 (79.5)	<0.001	0.001
Yes	23 (41.8)	25 (37.9)	502 (20.5)		
Family history of ovarian cancer up to first degree					
No	50 (90.9)	63 (95.5)	2429 (99.0)	<0.001	0.007
Yes	5 (9.1)	3 (4.5)	25 (1.0)		
Family history of ovarian cancer up to second degree					
No	49 (89.1)	63 (95.5)	2413 (98.3)	<0.001	0.078
Yes	6 (10.9)	3 (4.5)	41 (1.7)		
Bilateral breast cancer					
No	45 (81.8)	60 (90.9)	2321 (94.6)	<0.001	0.197
Yes	10 (18.2)	6 (9.1)	133 (5.4)		
Ovarian cancer					
No	53 (96.4)	65 (98.5)	2439 (99.4)	0.007	0.362
Yes	2 (3.6)	1 (1.5)	15 (0.6)		
Grade (%)					
I	1 (2.8)	0	236 (12.2)	<0.001	0.030
II	8 (22.2)	25 (52.1)	957 (49.4)		
III	27 (75.0)	23 (47.9)	746 (38.5)		
Lymph node					
Negative	30 (63.8)	24 (44.4)	1241 (56.6)	0.320	0.076
Positive	17 (36.2)	30 (55.6)	953 (43.4)		
Stage					
I	10 (23.8)	12 (23.5)	614 (30.1)	0.311	<0.001
II	21 (50.0)	18 (35.3)	1042 (51.1)		
III	10 (23.8)	13 (25.5)	291 (14.3)		
IV	1 (2.4)	8 (15.7)	93 (4.6)		
Oestrogen receptor					
Negative	38 (80.9)	11 (19.6)	759 (33.6)	<0.001	0.028
Positive	9 (19.1)	45 (80.4)	1497 (66.4)		
Progesterone receptor					
Negative	36 (83.7)	23 (44.2)	875 (43.0)	<0.001	0.857
Positive	7 (16.3)	29 (55.8)	1161 (57.0)		
Human epidermal growth factor 2					
Negative	43 (93.5)	44 (84.6)	1512 (70.5)	0.001	0.027
Positive	3 (6.5)	8 (15.4)	632 (29.5)		
Triple negative breast cancer					
No	9 (22.0)	43 (87.8)	1626 (82.9)	<0.001	0.369
Yes	32 (78.0)	6 (12.2)	336 (17.1)		
Ki-67					
Low	2 (33.3)	4 (57.1)	277 (64.1)	0.119	0.703
High	4 (66.7)	3 (42.9)	155 (35.9)		

^aUnless otherwise specified, data are presented in no. (%). For each data type, the total number of subjects may differ because of missing or incomplete data.

†*BRCA1* carriers versus non-*BRCA1/2* carriers.

‡*BRCA2* carriers versus non-*BRCA1/2* carriers.

age of 50 (78% and 66% for *BRCA1* and *BRCA2*, respectively). *BRCA1* and *BRCA2* carriers were also significantly more likely to have family history of breast or ovarian cancer and high grade tumours (grade III). In addition, *BRCA1* carriers were more likely to have bilateral breast cancer, personal history of ovarian cancer and TNBC, whereas *BRCA2* carriers were more likely to have oestrogen receptors positive breast cancers, human epidermal growth factor receptor negative breast cancer and later stage of breast cancer presentation (stage IV). Further comparison of the clinical and pathological characteristics of *BRCA1* and *BRCA2* carriers showed no differences in these variables among the different ethnic groups (see table 10 in the online supplementary file 1).

Predictive value of testing guidelines

In order to determine the appropriateness of using age of onset, family history and pathological features of breast cancer to identify women who may benefit most from genetic testing, we determined the proportion of women and carriers who fulfilled the criteria for the NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian (V.2.2017) and compared it with those who fulfilled the criteria for MyCPG for *BRCA1* and *BRCA2* testing. Both criteria included women with breast and ovarian cancer, bilateral breast cancer under the age of 50, male breast cancer and strong first-degree relative with breast cancer. However, the criteria differ in age of primary breast cancer (≤ 45 vs ≤ 35), age of onset of TNBC (≤ 60 vs ≤ 50) and the significance of family history of breast and other cancers. In the present study, 46% of patients with breast cancer, 91% of *BRCA1* carriers and 71% of *BRCA2* carriers fulfilled the NCCN criteria, whereas 24% of patients with breast cancer, 73% of *BRCA1* carriers and 50% of *BRCA2* carriers fulfilled the MyCPG criteria.

DISCUSSION

The prevalence of *BRCA1* and *BRCA2* deleterious variant carriers among Asian breast cancer cases has hitherto been largely investigated in a priori high-risk cohorts selected on the basis of age of diagnosis, family history of breast and ovarian cancer and to a limited extent, pathological features of the cancers.² To the best of our knowledge, this is the largest study involving full exon screening of *BRCA1* and *BRCA2* in an unselected series of Asian patients with breast cancer. We found *BRCA1* and *BRCA2* deleterious variants in 4.7% (95% CI 3.9% to 5.5%) of patients with breast cancer in this unselected hospital-based series, with the frequencies of *BRCA1* and *BRCA2* deleterious variants being similar. Comparison with previous clinical testing, including analysis of LGR, indicates a sensitivity of 90%, suggesting that the true prevalence would be approximately 5%–6%.

The population frequencies of *BRCA1* and *BRCA2* deleterious variant carriers in the controls were similar to that observed in the Exome Aggregation Consortium East Asians, at approximately 0.2% for each gene. Our results were also consistent with previous estimates of 0.4% *BRCA1* and *BRCA2* mutation carrier frequency in Caucasian population.^{23 24} The estimated breast cancer ORs associated with *BRCA1* and *BRCA2* deleterious variants (12.6 for both genes) were similar to those estimated in European populations.²⁵ These results suggest that *BRCA1* and *BRCA2* mutations are associated with similar relative risks in Asian and European populations, which would imply that the absolute risk of breast cancer in carriers would be lower in Asian women. However, the OR estimates have wide confidence limits, and larger studies will be needed to provide more precise estimates.

Consistent with previous studies,^{5 6 26 27} we show that carriers of both *BRCA1* and *BRCA2* deleterious variants were more likely than non-carriers to be diagnosed at a younger age, have family history of breast or ovarian cancer and high tumour grade. In addition, bilateral breast cancer, personal history of ovarian cancer and TNBC pathology were significantly associated with *BRCA1* deleterious variant carriers.

Full exon sequencing on an unselected series of patients with breast cancer allowed us to evaluate how often *BRCA1* and *BRCA2* deleterious variant carriers might be missed in clinical practice in a typical resource-constrained Asian country such as Malaysia. Using the more stringent MyCPG genetic testing criteria, only 24% of patients with breast cancer would be offered genetic counselling, but 40% of deleterious variant carriers would be missed. On the other hand, using the NCCN genetic testing criteria, 80% of deleterious variant carriers fulfilled the criteria and would therefore be offered genetic counselling, but nearly half (46%) of all patients with breast cancer would also need genetic counselling, making this a costly and potentially unaffordable risk-stratified management approach.

Notably, both NCCN genetic testing criteria and current risk prediction model underestimated *BRCA2* more significantly than *BRCA1* carriers. In this study, NCCN referral guidelines underestimated by threefold *BRCA2* carriers compared with *BRCA1* (29% vs 9%). The underdetection of *BRCA1* and *BRCA2* carriers by current genetic testing guidelines and risk prediction models may be accounted by the lower absolute risks associated with *BRCA1* and *BRCA2* mutations in Asians compared with Caucasians,^{28–30} the higher *BRCA2:BRCA1* mutation ratio in Asian patients with breast cancer to that of Caucasian^{2 5 6 26 31–33} compounded by under-reporting of family history of breast cancer cases in Asian settings,^{7 34} and lower population incidence rates of breast cancer in Asian compared with Caucasian populations.³⁵ This highlights a need for additional biomarkers or methods to identify Asian women who would benefit from genetic counselling and genetic testing, particularly in families with insignificant family history from resource-constrained settings.

With the availability of Asian-specific estimates of *BRCA1* and *BRCA2* carrier prevalence in unselected patients with breast cancer and unaffected population, and the risk estimates conferred by these genes, these may guide modifications to existing models and testing guidelines, or development of novel ones, to predict *BRCA1* and *BRCA2* carriers more accurately in Asian individuals.^{36 37}

One limitation of our study is that LGRs were not included because MLPA was not performed in all patients with breast cancer. Furthermore, some carriers may have been missed due to the sensitivity of our amplicon-based sequencing approach.

CONCLUSION

Five per cent of unselected Asian patients with breast cancer are carriers of germ line deleterious variants in *BRCA1* or *BRCA2* and approximately 80% of carriers would have been offered genetic counselling based on current NCCN screening criteria. Our study provides the foundation for developing risk assessment tools for the Asian population, and highlights the need for cost-effective strategies to triage women for genetic counselling and testing in low-resource settings.

Author affiliations

¹Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia

²Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK

³Department of Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA

⁴Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK

⁵Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec, Canada

⁶Sime Darby Medical Centre, Subang Jaya, Selangor, Malaysia

⁷Faculty of Medicine, Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya, Kuala Lumpur, Malaysia

⁸Department of Surgery, Faculty of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia

⁹Department of Applied Mathematics, Engineering, The University of Nottingham Malaysia Campus, Semenyih, Selangor, Malaysia

Acknowledgements The authors would like to thank the participants and their families for taking part in this study. We thank Phuah Sze Yee, Tan Min Min, Norhashimah Hassan, Maheswari Jaganathan, Leelavathy D/O Krishnan, Faridah Binti Bakri and Thong Meow Keong for assistance with recruitment of patients, data cleaning, tissue collections, DNA preparation and helpful discussions.

Contributors Acquisition of data and analysis and interpretation of data: WXW, JA, KNL, SM, SNH, PSN, DS-CL, SYL, SYY, JL, SYL, BD, KP, LD, CL, CB, DC, PH, JS, CHY, NAMT, WKH, ACA and AMD. Manuscript writing: WXW and SHT. Conception and design: SHT and DFE. All authors equally contributed to the critical review and final approval of manuscript

Funding This study was funded by research grants from the Wellcome Trust (203477/Z/16/Z), Ministry of Higher Education to University Malaya (UM.C/HIR/MOHE/06), Estee Lauder Group of Companies, Cancer Research Malaysia, Cancer Research UK (C1287/A16563 to DFE, C8197/A16565 to AMD and C12292/A20861 to ACA), the European Union's Horizon 2020 Research and Innovation Programme under grant agreement 634935 (BRIDGES) and the PERSPECTIVE project, funded from the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministère de l'Économie, de la Science et de l'Innovation du Québec through Genome Québec and the Quebec Breast Cancer Foundation. BD was supported by the Intramural Research Program of the National Human Genome Research Institute.

Competing interests None declared.

Patient consent Obtained.

Ethics approval Medical Ethics Committee of University Malaya Medical Centre (application number: 842.9) and the Independent Ethics Committee of Sime Darby Medical Centre (application numbers: 201109.4 and 201208.1).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372:2243–57.
- Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, Weitzel JN, Siu MT, Law FB, Chan TL, Narod SA, Ford JM, Ma ES, Kim SW. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *J Med Genet* 2016;53:15–23.
- Buyss SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, Sharma L, Saam J, Lancaster J, Daly MB. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. *Cancer* 2017;123:1721–30.
- Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olsowid C, Slettedahl S, Hallberg E, Guidugli L, Davila JJ, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Peltari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. *J Clin Oncol* 2015;33:304–11.
- Zhang J, Sun J, Chen J, Yao L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. *Breast Cancer Res Treat* 2016;158:455–62.
- Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, Zhuang ZG, Cao AY, Ling H, Yu KD, Li S, Sun MH, Zhou XY, Huang W, Shao ZM. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2,991 patients and 1,043 controls by next-generation sequencing. *Int J Cancer* 2017;141:129–42.
- Nakamura S, Kwong A, Kim SW, Iau P, Patmasiriwat P, Dofitas R, Aryandono T, Hu Z, Huang CS, Ginsburg O, Rashid MU, Sarin R, Teo SH. Current status of the management of hereditary breast and ovarian cancer in Asia: first report by the Asian BRCA consortium. *Public Health Genomics* 2016;19:53–60.
- Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kakkiani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. *J Natl Compr Canc Netw* 2014;12:1326–38.
- Gomez SL, Quach T, Horn-Ross PL, Pham JT, Cockburn M, Chang ET, Keegan TH, Glaser SL, Clarke CA. Hidden breast cancer disparities in Asian women: disaggregating incidence rates by ethnicity and migrant status. *Am J Public Health* 2010;100(Suppl 1):S125–31.
- Wen WX, Soo JS, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, Mohd Taib NA, Teo SH. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. *Breast Cancer Res* 2016;18:56.
- Mariapun S, Li J, Yip CH, Taib NA, Teo SH. Ethnic differences in mammographic densities: an Asian cross-sectional study. *PLoS One* 2015;10:e0117568.
- Phuah SY, Looi LM, Hassan N, Rhodes A, Dean S, Taib NA, Yip CH, Teo SH. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. *Breast Cancer Res* 2012;14:R142.
- Ng PS, Wen WX, Fadlullah MZ, Yoon SY, Lee SY, Thong MK, Yip CH, Mohd Taib NA, Teo SH. Identification of germline alterations in breast cancer predisposition genes among Malaysian breast cancer patients using panel testing. *Clin Genet* 2016;90:315–23.
- Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. *Breast Cancer Res* 2008;10:R59.
- Kang P, Mariapun S, Phuah SY, Lim LS, Liu J, Yoon SY, Thong MK, Mohd Taib NA, Yip CH, Teo SH. Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families. *Breast Cancer Res Treat* 2010;124:579–84.
- Decker B, Allen J, Luccarini C, et al. Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. *J Med Genet* 2017;54:732–41.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754–60.
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–303.
- Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38:e164.
- Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. *J Med Genet* 2006;43:295–305.
- Kwong A, Ng EK, Wong CL, Law FB, Au T, Wong HN, Kurian AW, West DW, Ford JM, Ma ES, Ek N, Es M. Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. *PLoS One* 2012;7:e43994.
- Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Czene K, Iwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, van der Luijt RB, Hein R, Dahmen N, Beckman L, Meindl A, Schmutzler RK, Müller-Miyshok B, Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, Uitterlinden AG, Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Caniusius S, Wessels LF, Haiman CA, Shah M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger H, Couch FJ, Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens R, Christiaens MR, Rudolph A, Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van der Schoot CE, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Perez JJ, Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MW, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL, Knight JA, Glendon G,

- Mulligan AM, Lindblom A, Margolin S, Hoening MJ, Hollestelle A, van den Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Müller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Brüning T, Radice P, Peterlongo P, Manoukian S, Bonanni B, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Bogdanova NV, Antonenkova NN, Dörk T, Kristensen VN, Anton-Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo KY, Noh DY, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Shu XO, Lu W, Gao YT, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK, Hartman M, Miao H, Lim WY, Sng JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsana P, Shen CY, Hsiung CN, Wu PE, Ding SL, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Simard J, Garcia-Closas M, Pharoah PD, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF. Breast and Ovarian Cancer Susceptibility Collaboration; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); kConFab Investigators; Australian Ovarian Cancer Study Group; GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet* 2013;45:353–61.
- 23 Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, Passini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjäkoski K, Kallioniemi OP, Eerola H, Nevanlinna H, Pharoah PD, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer* 2008;98:1457–66.
- 24 Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, Gayther SA, Goode EL, Pharoah PD. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Hum Mol Genet* 2014;23:4703–9.
- 25 Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC Consortium of Investigators of Modifiers of BRCA1/2; Breast Cancer Association Consortium. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. *Br J Cancer* 2014;110:535–45.
- 26 Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP, Garber JE. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with Breast Cancer. *J Clin Oncol* 2016;34:1460–8.
- 27 Atchley DP, Albarracín CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. *J Clin Oncol* 2008;26:4282–8.
- 28 Park B, Dowty JG, Ahn C, Win AK, Kim SW, Lee MH, Lee JW, Kang E, Hopper JL, Park SK. Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2. *Breast Cancer Res Treat* 2015;152:659–65.
- 29 Yao L, Sun J, Zhang J, He Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. *Breast Cancer Res Treat* 2016;156:441–5.
- 30 Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007;25:1329–33.
- 31 Høberg-Vetti H, Bjørvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listol W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONUS study. *Eur J Hum Genet* 2016;24:881–8.
- 32 Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. *BMC Cancer* 2017;17:438.
- 33 Zhong X, Dong Z, Dong H, Li J, Peng Z, Deng L, Zhu X, Sun Y, Lu X, Shen F, Su X, Zhang L, Gu Y, Zheng H. Prevalence and prognostic role of BRCA1/2 variants in unselected Chinese breast cancer patients. *PLoS One* 2016;11:e0156789.
- 34 Ginsburg OM, Dinh NV, To TV, Quang LH, Linh ND, Duong BT, Royer R, Llacuachacqui M, Tulman A, Vichodez G, Li S, Love RR, Narod SA. Family history, BRCA mutations and breast cancer in Vietnamese women. *Clin Genet* 2011;80:89–92.
- 35 DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. *Cancer Epidemiol Biomarkers Prev* 2015;24:1495–506.
- 36 Marroni F, Aretini P, D'Andrea E, Caligo MA, Cortesi L, Viel A, Ricevuto E, Montagna M, Cipollini G, Federico M, Santarosa M, Marchetti P, Bailey-Wilson JE, Bevilacqua G, Parmigiani G, Presciuttini S. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. *Eur J Hum Genet* 2004;12:899–906.
- 37 Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM. Performance of BRCA1/2 mutation prediction models in Asian Americans. *J Clin Oncol* 2008;26:4752–8.